The Problem with Both Mistakes

Under-supply stops a clinical trial. Patients cannot be dosed, sites go on hold, and the timeline slips in ways that are expensive and sometimes impossible to recover. The consequences are obvious and everyone works hard to avoid them.

Over-manufacturing is less dramatic but equally costly. A 10 kilogram GMP batch of an HPAPI drug product that was never used represents not just the direct manufacturing cost, but the slot on the manufacturing schedule, the stability testing, the storage fees, and the disposal costs when it expires. For complex or expensive drug products, over-manufactured material that is destroyed at expiry can represent a significant proportion of the total clinical development budget.

The goal of clinical supply planning is not to avoid one of these outcomes. It is to navigate intelligently between both of them.

The Variables That Make Clinical Supply Hard to Plan

Enrolment Uncertainty

Clinical trial enrolment is notoriously hard to predict. Sponsors routinely underestimate the time needed to identify eligible patients, obtain consent, and complete screening. An enrolment model that assumes 100% of sites are active from month one, and that each site enrols patients at the projected rate, is an optimistic model that will almost always overestimate how quickly supply is consumed.

Protocol Amendments

Protocol amendments change the treatment duration, the dosing regimen, or the patient population. Each amendment is a supply planning event. An amendment that extends the treatment period from 12 weeks to 24 weeks doubles the supply requirement per patient. An amendment that adds a new cohort requires material that may not have been manufactured yet.

Drug Wastage

Unused drug at each clinical site, partially used kits, returned doses, and material destroyed due to temperature excursions all represent supply losses that must be planned for. Wastage rates vary by dosage form, route of administration, and site logistics, but assuming zero wastage is unrealistic.

The Statistical Approach: Probability of Sufficient Supply

Rather than planning to a single expected scenario, best-practice clinical supply planning uses simulation to generate a probability distribution of supply outcomes. Monte Carlo simulation, using distributions for enrolment rate, dropout rate, and wastage rather than point estimates, gives the supply planner a risk profile rather than a single number.

The output is a probability of sufficient supply (PoSS) at each potential manufacturing quantity. The sponsor then makes an informed decision about the trade-off between manufacturing more (higher PoSS, higher cost) and manufacturing less (lower cost, higher risk of supply shortage). For a Phase III pivotal trial, a PoSS of 95% might be acceptable. For an exploratory Phase I study, a lower threshold might be appropriate given the higher likelihood of protocol change.

Supply Planning Approaches by Trial Phase

Trial Phase	Typical Supply Strategy	Key Planning Assumptions
Phase I SAD/MAD	Single manufacturing campaign covering all cohorts plus safety margin; conservative overage	Small patient numbers; tight dose range; cohort-by-cohort release allows staged manufacture if needed
Phase I/II first-in-class	Two campaigns: initial supply for early cohorts; second campaign triggered by interim data	High uncertainty in enrolment and dose selection; adaptive manufacture preferred over single large campaign
Phase II proof-of-concept	Statistical supply model; manufacture to defined PoSS; rolling resupply trigger defined	Enrolment modelling using investigator projections; monthly supply review meetings
Phase III global	Full Monte Carlo simulation; regional depot strategy; safety stock at each depot	Site-level enrolment projections; wastage rates from Phase II; country-specific import lead times
Adaptive design trials	Supply model updated at each interim analysis; flexible manufacturing agreements with CDMO	Scenario planning for each adaptive arm; close coordination between statistical and supply planning teams

The Packaging and Labelling Layer

Supply planning is not just about how much drug to manufacture. It is also about how to package it. A single GMP bulk batch can be held and packaged into country-specific labelled kits as the trial progresses, allowing the labelling to be adapted to the actual trial countries without over-commitment to a specific national market early in the programme.

This just-in-time packaging approach requires a CDMO with clinical packaging capability and a project management model that coordinates the packaging schedule with the enrolment forecast. The alternative, packaging everything upfront for all anticipated markets, results in large amounts of labelled material that may expire before it is used if enrolment in specific markets is slower than projected.

How Ardena Supports Clinical Supply Planning

Ardena’s clinical supply team at Assen works with sponsors to develop supply models, design packaging strategies, and manage the coordination between GMP manufacturing, clinical packaging, and global distribution. The team has experience across Phase I through Phase III programmes and can support both simple fixed-supply and complex adaptive supply strategies.

The Last Mile Problem in Clinical Supply

A clinical trial can have the most rigorous bioanalytical programme and the most carefully designed protocol in the world, but if the investigational medicinal product (IMP) does not arrive at the investigator site in the right condition, at the right time, and with the right documentation, none of that matters. Global clinical distribution is the operational backbone of a clinical trial, and it is one of the most underestimated sources of risk in early-phase programmes.

For a Phase I trial running at a handful of sites in Western Europe, the logistical challenges are manageable. As a programme grows and extends to sites in multiple continents, the complexity of customs requirements, depot management, cold chain maintenance, and country-specific regulatory documentation multiplies quickly.

The Regulatory Dimension of IMP Distribution

Investigational medicinal products are not commercial pharmaceutical products, and they are not treated as such by customs authorities. They require specific import licences, certificates of analysis, manufacturing authorisation documentation, and, in many countries, additional country-specific approvals before they can legally be imported for clinical use. The EU Clinical Trials Regulation (EU) 536/2014 and its associated guidance on IMP manufacturing and supply set the framework for European clinical supply, while individual non-EU markets each have their own import requirements that must be navigated separately.

The consequences of getting this wrong are not minor. IMP held in customs clearance for two weeks because of a documentation error means two weeks of delay to site activation, which means two weeks of delay to first patient dosing, which in a competitive therapeutic area can have real consequences for programme timelines and funding milestones.

Clinical Supply Distribution Models

Distribution Model	How It Works	Best Suited For	Key Consideration
Direct to site	IMP shipped from manufacturer directly to each investigator site	Simple programmes; small number of sites; stable ambient products	High volume of individual shipments; complex for multi-country programmes
Central depot	IMP shipped to a single central depot, then distributed to sites as needed	Multi-site, multi-country trials; products requiring controlled storage	Depot must hold appropriate storage authorisations; adds handling step
Regional depots	Multiple regional depots covering different geographic zones	Phase III trials with large numbers of sites across multiple continents	Higher cost; requires coordination between depots; preferred for cold chain products
Investigator site as depot	Sites hold small buffer stock and request resupply as needed	Adaptive trials; variable dosing schedules	Requires on-site storage capability and electronic IMP tracking

Cold Chain Management in Global Distribution

Many investigational products require storage and transport at controlled temperatures, ranging from standard refrigerated conditions at 2 to 8 degrees Celsius through to deep frozen at minus 20 degrees Celsius or minus 80 degrees Celsius for cell therapies and some biologic products. Maintaining the cold chain across an international distribution network, through multiple handling steps, customs inspections, and last-mile delivery, requires validated packaging, temperature monitoring, and documented procedures for managing excursions.

Temperature excursion management is an area where clear decision trees and pre-defined acceptance criteria save significant time during a trial. When a temperature excursion is recorded, the sponsor needs to be able to determine quickly, using validated stability data, whether the product is still fit for use or needs to be quarantined. Having this process documented and tested before the trial starts prevents ad hoc decisions under time pressure.

Country-Specific Challenges Worth Planning For

Named Patient and Compassionate Use Requirements

In some markets, investigational products can only be imported on a named patient basis, which requires individual import licences linked to specific patient identifiers. This creates significant administrative overhead for trials with large numbers of sites in those markets and requires close coordination between the clinical operations team, the regulatory team, and the clinical supply partner.

Labelling Requirements

Clinical trial labelling requirements vary by jurisdiction. In the EU, Annex 13 of the EU GMP guidelines sets out the labelling requirements for IMPs, including the mandatory elements and the language requirements for each member state. Markets outside the EU may require additional information on the label or translated labels. Designing a master label that can be adapted for all required markets, while remaining within the physical dimensions of the packaging, is a practical challenge that benefits from early planning.

Controlled Substance Scheduling

Clinical programmes involving controlled substances, including psychedelics, opioids, or other scheduled compounds, face additional requirements at every border crossing. Import licences, permits, and sometimes individual authorisations from national regulatory authorities are required. The lead times for obtaining these permits can be significant and must be built into the programme timeline.

How Ardena Manages Global Clinical Supply

Ardena’s clinical supply team, based at the Assen facility in the Netherlands and coordinated across the wider European network, provides IMP packaging, labelling, storage, and distribution services for clinical trials across Europe and to international markets. The team manages customs documentation, depot coordination, and cold chain logistics for programmes ranging from single-site Phase I studies to multi-country Phase II trials.

Where Clinical Data Is Actually Lost

In a well-designed clinical trial, the analytical plan, the bioanalytical methods, the statistical model, and the regulatory strategy all receive careful attention. What often receives less attention is the physical act of collecting, labelling, processing, and shipping the biological samples that all of that methodology depends on. Yet errors at the sample collection stage produce data that is unusable, and unusable samples translate directly into missing data points that can weaken the statistical confidence of the study or trigger protocol deviation reports that complicate the regulatory submission.

The most common sources of clinical sample error are not wilful or random. They are predictable failures driven by poorly designed clinical trial kits, inadequate site training, or logistical processes that are too complex for a busy nurse or clinical site coordinator to execute reliably under time pressure.

The Most Common Clinical Sample Errors and Their Causes

Error Type	Common Cause	Consequence	Prevention Strategy
Sample mislabelling	Manual label application; ambiguous label format; no barcode	Sample cannot be attributed to patient or timepoint; data lost	Pre-printed barcode labels; one label per tube design; kit personalisation to patient ID
Incorrect tube type	Multiple tube types in kit without clear differentiation	Anticoagulant incompatibility; sample unusable	Colour-coded tubes with unambiguous visual hierarchy; single visit type per kit
Wrong processing procedure	Complex centrifugation steps without clear instruction	Incorrect matrix; haemolysis; cells not separated	Laminated step-by-step processing card; pictorial instructions; pre-centrifuged tube option
Missed timepoint	No alert for critical PK sample windows	Sparse PK profile; impaired PK modelling	Electronic alert system or timed label cards; site coordinator checklist
Incorrect storage or temperature excursion	Samples stored at room temperature pending shipment	Analyte degradation; stability failure	Cool packs integrated into kit; clear storage instruction on every tube
Shipping documentation error	IATA documentation incomplete or missing	Sample held in customs; delayed or refused delivery	Pre-completed customs documentation; clinical supply partner coordinates shipping

Principles of Good Clinical Trial Kit Design

Design for the Least Experienced User

A clinical trial kit will be used by nurses and site coordinators at dozens of different sites, with different training backgrounds, different levels of familiarity with clinical research, and different workloads on the day of the visit. The kit design must be idiot-proof in the literal sense: it should make the correct action the easiest action, and the incorrect action difficult or impossible to take by accident.

Minimise the Number of Decisions the Site Must Make

Every decision that the site is required to make at the point of sample collection is an opportunity for an error. Pre-labelled tubes eliminate the labelling decision. Visit-specific kits that contain only the tubes needed for that visit eliminate the tube selection decision. Pre-positioned cool packs that are activated automatically when the kit is opened eliminate the storage decision. Good kit design removes decisions, not adds instructions about how to make them.

Test the Kit in a Simulated Use Environment

Before a clinical trial kit goes to sites, it should be tested by people who represent the intended users but who were not involved in designing it. Simulated use testing often reveals ambiguities and failure modes that are invisible to the design team but obvious to a nurse encountering the kit for the first time. This investment at the design stage prevents protocol deviations at the collection stage.

Patient Kit Services at Ardena

Ardena’s clinical supply and bioanalytical teams at Assen provide end-to-end patient kit services for clinical trials, from kit design through to sample receipt and processing. Kits are assembled and quality-checked at Assen, with pre-labelled tubes, visit-specific configurations, and integrated cold chain components as standard.

Ardena coordinates clinical sample logistics including temperature-controlled shipping from investigator sites across Europe and beyond, customs documentation for international shipments, and chain-of-custody tracking from site to laboratory. The same team that designs the kit is responsible for receiving and processing the samples, creating a closed-loop system where kit design decisions are informed by direct experience of what goes wrong in transit and at the bench.

Rare Disease Development Is a Different Kind of Problem

The clinical supply challenges in rare disease drug development are categorically different from those in standard pharmaceutical programmes. Patient populations are small, sometimes in the dozens rather than the thousands. The drug may be highly potent, genetically targeted, or manufactured using a technology platform with limited redundancy. Each individual dose can represent a disproportionately high cost relative to conventional therapeutics. And the consequence of a supply failure is not a delayed commercial shipment but a delayed patient dose that may have no alternative.

Building a resilient supply chain for a rare disease programme requires a different mindset and, often, a different type of CDMO partner.

The Specific Challenges of Rare Disease Supply

Small Batch Sizes

Standard GMP manufacturing processes and equipment are optimised for batch sizes that may be many times larger than what a rare disease programme requires. Running small batches efficiently, without compromising yield, analytical testing coverage, or the cost-per-dose economics, requires manufacturing processes specifically designed for small-scale production. Not all CDMOs have the equipment configuration and operational experience to do this well.

High-Value API Management

In a rare disease programme, the drug substance is often extremely expensive to produce. A failed GMP batch does not just mean a delay. It may mean a six-month wait for the next batch of API. Supply chain resilience therefore starts with process robustness: ensuring that the manufacturing process has sufficient design space that it succeeds reliably rather than at the limits of its capability.

Adaptive Trial Design Complexity

Many rare disease clinical trials use adaptive designs that allow the protocol to be modified based on interim data. From a supply chain perspective, this creates planning complexity: you need to hold enough clinical supply to support protocol expansions or changes, while avoiding overproduction of a high-cost drug for a small patient population. EMA guidance on adaptive trial designs acknowledges the particular challenges of adaptive studies and provides a framework for managing the interaction between trial design and drug supply.

Global Distribution to Low-Volume Sites

Phase II and III trials in rare diseases often require distribution to clinical sites across multiple countries, each receiving very small quantities of study drug. Standard clinical supply logistics assume larger shipments to more sites. Rare disease supply chains need solutions that can handle country-specific regulatory requirements, small-parcel cold chain, and the documentation requirements of each jurisdiction without the economies of scale that come with conventional clinical supply.

Rare Disease Supply Chain: Key Capability Requirements

Capability	Why It Matters for Rare Disease	Ardena Capability
Small-batch GMP manufacturing	Patient populations may require fewer than 100 doses per batch	Available across Ghent, Pamplona, and Oss sites
HPAPI handling	Many rare disease drugs are highly potent	OEB 3-5 containment available at Pamplona
Lyophilisation	Common formulation strategy for biologic rare disease drugs	Available at Ghent
Clinical packaging and labelling	Complex country-specific requirements for small volumes	Available at Ghent and Assen
Stability management	Long-duration stability to support extended trial periods	GMP stability storage across multiple sites
CMC regulatory writing	Orphan designation has specific CMC implications	Integrated regulatory team, multi-jurisdictional experience

The Orphan Drug Designation Dimension

Orphan Drug Designation (ODD), available through both the FDA and EMA, provides significant incentives for rare disease drug development, including fee waivers, regulatory assistance, and market exclusivity on approval. The designation also has CMC implications. The EMA’s ODD criteria include a requirement to justify the patient population size, and the CMC package for an orphan drug application may be reviewed with different data expectations than a standard application.

Ardena’s regulatory team has experience preparing CMC packages for programmes with orphan designation across both jurisdictions. Our related article on Preparing Module 3 of the CTD: A Practical Guide covers the CMC filing requirements relevant to rare disease programmes.

How Ardena Supports Rare Disease Programmes

Ardena’s manufacturing facilities are configured to handle small-batch GMP production efficiently, including for high-potency compounds at the Pamplona site and for complex injectables and lyophilised products at Ghent. The clinical supply team at Assen manages clinical packaging, labelling, and distribution across multiple markets for programmes with complex logistics requirements.

For rare disease programmes at any stage of development, Ardena’s integrated model means that the manufacturing strategy, the regulatory approach, and the clinical supply plan are developed together rather than sequentially, reducing the risk of misalignment that can cause delays at the worst possible moment.

The Cost of Finding Problems Late

In pharmaceutical development, the same problem costs vastly different amounts depending on when it surfaces. A solubility issue identified during pre-formulation screening costs a few weeks and a reformulation study. The same issue discovered during a GMP manufacturing campaign costs that, plus the failed batch, plus the regulatory amendment, plus the delay to your clinical timeline.

Early-stage drug development is fundamentally about de-risking. The goal is to surface the problems that could derail your programme when they are still cheap to fix, and to build the evidence base that lets you move into GMP manufacturing with confidence.

The Most Common Formulation Showstoppers

Risk Category	Common Manifestation	When It Surfaces Without Mitigation	Mitigation Approach
Poor aqueous solubility	Drug precipitates in dissolution, low bioavailability	Phase I PK disappointment	BCS classification, solubility screening, ASD or nanosuspension strategy
Polymorphic instability	Crystal form converts during processing or storage	Stability failure post-GMP	Polymorph screening, XRPD monitoring, controlled manufacturing conditions
Chemical instability	API degrades under heat, light, or humidity	OOS stability data	Stress testing, excipient compatibility, packaging selection
Manufacturability issues	Blend flows poorly, tablets cap or laminate	Failed GMP batch	Small-scale feasibility studies, equipment-specific evaluation
Bioavailability gap	Animal PK does not translate to human	Phase I PK/PD failure	Human-predictive dissolution, in vitro in vivo correlation modelling

Building a De-Risking Strategy for Your Molecule

Start with the Physical Chemistry

Before any formulation work begins, a thorough characterisation of the API’s physical chemistry is essential. Solubility across the pH range relevant to the GI tract, log P or log D, pKa, melting point, thermal behaviour, and hygroscopicity all inform which formulation strategies are viable and which are not. ICH Q6A provides the quality test procedures framework for new drug substances that underpins this characterisation work.

Do Not Skip Solid-State Screening

The crystal form you first synthesise is rarely the best one for a stable, manufacturable drug product. Polymorph screening identifies the energetically stable forms and establishes which form you are working with. Salt selection can dramatically improve solubility and chemical stability. Conducting this work early, before a crystalline form becomes locked into your process, avoids expensive changes later.

Stress Testing Before GMP

Accelerated and stress stability studies run at high temperature, humidity, and under photolytic conditions are a standard way to predict the degradation behaviour of a new molecule and its formulated product. Running abbreviated stress studies before committing to a formulation approach is a low-cost insurance policy against stability surprises in GMP storage.

How Ardena Builds De-Risking into Every Programme

Ardena’s development programmes are structured around progressive de-risking. The solid-state research team in Ghent conducts polymorph and salt screening as an integrated part of the formulation strategy, not as a standalone activity. The analytical teams develop methods that are fit for purpose at each stage, rather than designing GMP-validated methods before the formulation is stable.

When pre-formulation data suggests a solubility challenge, the team can draw on a range of enabling technologies, including amorphous solid dispersions by spray drying or hot melt extrusion, nanosuspensions, and lipid-based formulations, depending on the molecule’s properties and the target product profile.

For most small and mid-size biotech companies, getting to first-in-human (FIH) dosing as quickly as possible is an existential priority. Clinical data is the currency of biotech fundraising. Every month between selecting a candidate and dosing the first patient in a Phase I study is a month during which a competitor may be generating data, a month during which your runway is shortening, and a month during which your thesis is untested.

Compressing the FIH timeline is not about cutting corners. It is about identifying the activities that are on the critical path, running parallel workstreams where the science allows, and building a development plan that avoids the common causes of delay.

Where Time Is Actually Lost

Stage	Common Delay Cause	Typical Time Lost
Pre-formulation	Solid-state screening not started until API is available	4-8 weeks
Formulation development	Sequential rather than parallel solubility and stability work	6-12 weeks
Analytical method development	GMP-level methods designed before formulation is stable	4-8 weeks
CMC dossier preparation	Regulatory writing starts late, after all data is available	4-8 weeks
GMP manufacturing	CDMO slot not reserved in advance, tech transfer takes longer than expected	8-16 weeks
IND/IMPD review	CMC deficiencies due to incomplete or inconsistent data	3-6 months (FDA response cycle)

Strategies for Compressing the Timeline

Start Solid-State Work Before the API Synthesis Is Complete

Polymorph screening and salt selection require API material, but they do not require final, fully characterised API at commercial purity. Starting with earlier-stage material from chemical development and running solid-state work in parallel with final synthesis optimisation can save four to six weeks without adding scientific risk, provided the synthetic route is sufficiently stable.

Use a Formulation-First Mindset

The target product profile should drive formulation strategy from day one. If you know the target dose, the intended patient population, and the required release profile before pre-formulation begins, the screening work is more focused. Bioavailability-enhancing technologies such as amorphous solid dispersions or nanosuspensions should be evaluated in parallel with simpler approaches rather than as a sequential fallback. ICH Q8(R2) on pharmaceutical development describes the design space concept that supports this structured, front-loaded approach.

Develop Methods Fit for Purpose, Not Fit for Filing

A common source of wasted time is developing fully validated GMP analytical methods before the formulation is stable. Early development analytical methods need to be accurate, reproducible, and suitable for the decisions being made at that stage. They do not need to meet the validation criteria required for GMP release until the formulation and process are sufficiently locked. Phasing method development appropriately frees capacity and avoids rework.

Book Your GMP Slot Before You Need It

GMP manufacturing capacity at reputable CDMOs is typically booked six to twelve months in advance. If you wait until your formulation is finalised before engaging with a manufacturing partner, you will wait. Engaging early, sharing your development timeline, and reserving a provisional slot before the technical package is complete is standard practice for programmes with aggressive timelines.

Write the CMC Section Progressively

The CMC section of an IND or IMPD does not have to be written in one sprint at the end of development. A regulatory team that is integrated with the development programme writes sections as the data is generated, so that by the time the last experiment is complete, the dossier is 80% written. This approach also surfaces regulatory questions early, when there is still time to address them without delaying the filing.

How Ardena Builds Speed into Development Programmes

Ardena’s integrated model is specifically designed to support compressed FIH timelines. The solid-state team, formulation scientists, analytical chemists, and regulatory advisors work on the same programme, sharing data in real time and making decisions together rather than sequentially. GMP manufacturing capacity at Ardena’s sites can be provisionally reserved as part of the development agreement, removing the CDMO slot booking risk from your critical path.